<DOC>
	<DOCNO>NCT00697775</DOCNO>
	<brief_summary>In study safety immunogenicity 2 different formulation candidate HBV-MPL vaccine administer accord 0 , 6-month schedule explore compare Engerix™-B healthy adolescent age 11 15</brief_summary>
	<brief_title>Safety Immunogenicity GSK Bio 's Candidate HBV-MPL Vaccines Compared Engerix™-B , Healthy Adolescents</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age : 11 15 year time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain parent guardian subject subject himself/herself subject 15 year age . If subject female , must nonchildbearing potential , childbearing potential , must abstinent use adequate contraceptive one month prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series Use investigational nonregistered drug vaccine study vaccine ( ) study period within 30 day precede first dose study vaccine . Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within six month vaccination . Planned administration vaccine foreseen study protocol period start one week dose vaccine end 30 day . Previous vaccination hepatitis B virus . Previous vaccination vaccine contain MPL . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrollment . Hepatomegaly , right upper quadrant abdominal pain tenderness . Axillary temperature ≥ 37.5° C. Administration immunoglobulin / blood product within six month precede first dose study vaccine plan administration study period . Pregnant lactate female . History chronic disease deem investigator relevant . Positive antiHBV antibody screen</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>